medigraphic.com
ISSN 1727-897X (Electronic)

2020, Number 6

<< Back Next >>

Medisur 2020; 18 (6)

Characterization of patients with bradyarrhythmias treated at the Cienfuegos Cardiology service (2018-2019)

Sánchez SS, Echazabal LM, Navarro BAL, Sánchez RE

Language: Spanish
References: 25
Page: 1110-1121
PDF size: 487.35 Kb.


ABSTRACT

Background: The creation of a bradyarrhythmias consultation in Cienfuegos, since 2017, has made possible the treatment and more specific follow-up of affected patients. Therefore, the study of its clinical and paraclinical characteristics is relevant.
Objective: to characterize patients with non-reversible bradyarrhythmias from the clinical point of view.
Methods: an observational, descriptive, cross-sectional study was carried out. All the patients seen by the Cardiology Service with a diagnosis of non-reversible bradyarrhythmia (N = 214) were taken into account to this work. Clinical, electrocardiographic, ergometric and echocardiographic variables were studied. Each one was given the statistical treatment according to its distribution, scale and type.
Results: Male sex predominated. The median age was 74 years. Hypertension was the most frequent comorbidity. The echocardigraphic study showed some type of structural alteration in the 80% of the patients. The most common etiology was fibrosis of the excito-conductor system (77%), as well as third degree atrioventricular block was the most common electrocardiographic diagnosis among those who received temporary and permanent pacemaker implantation. There was a low rate of complications.
Conclusion: the studied population was characterized as aged; with the presence of comorbidities; with some type of structural alteration in the majority, demonstrated through echocardiographic study. Fibrosis of the excito-conductive system and ischemic were the main causes of non-reversible bradyarrhythmia.


REFERENCES

  1. Yusuf S, Joseph P, Rangarajan S, Islam S, Mente A, Hystad P, et al. Modifiable risk factors, cardiovascular disease, and mortality in 155?722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Lancet. 2020;395(10226):795-808.

  2. Honarbakhsh S, Hunter L, Chow A, Hunter RJ. Bradyarrhythmias and pacemakers. BMJ. 2018;360:k642.

  3. Kusumoto FM, Schoenfeld MH, Barrett C, Edgerton JR, Ellenbogen KA, Gold MR, et al. 2018 ACC/AHA/HRS guidelines on the evaluation and management of patients with bradycardia and cardiac conduction delay: a report of the American College of Cardiology/American Heart Association Task Forceon Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2019;140(8):e382-482.

  4. Brignole M, Moya A, de Lange F, Deharo J, Elliott P, Fanciulli A, Fedorowsk A, Furlan R, et al. 2018 ESC Guidelines for the diagnosis and management of syncope 2018 ESC Guidelines for the diagnosis and management of syncope. European Heart Journal. 2018;39(21):1883-1948.

  5. Sidhu S, Marine J. Evaluating and managing bradycardia. Trends Cardiovasc Med. 2020;30(5):265-72.

  6. Alderete JF, Centurión OA. Conceptos actuales sobre la clasificación clínica y alteraciones electrofisiológicas en la disfunción del nódulo sinusal. Mem Inst Investig Cienc Salud [revista en Internet]. 2018 [citado 8 Jun 2020];16(2):[aprox. 20p]. Disponible en: https://revistascientificas.una.py/index.php/RIIC/article/view/1309.

  7. Miller M, Neuzil P, Dukkipati S, Reddy V. Leadless Cardiac Pacemakers. J Am Coll Cardiol. 2015;66(10):1179-89.

  8. Mateas RF, Tello MS, Jiménez PM, Ferrer MJ, Leal del Ojo J, Medina GD, et al. Novedades en estimulación cardíaca. Rev Esp Cardiol [revista en Internet]. 2008 [citado 3 Jun 2020];61 Suppl 1:[aprox. 39p]. Disponible en: https://www.revespcardiol.org/es-pdf-13114648.

  9. Eliasson H, Sonesson SE, Salomonsson S, Skog A, Wahren M, Gadler F. Outcome in young patients with isolated complete atrioventricular block and permanent pacemaker treatment: A nationwide study of 127 patients. Heart Rhythm. 2015;12(11):2278.

  10. Vries L, Dijk W, Hooijschuur C, Leening M, Stricker N, Van Hemel N. Utilisation of cardiac pace makers over a 20-year period: Results from a nation wide pac emaker registry. Neth Heart J. 2017;25(1):47-55.

  11. Arribas F, Auricchio A, Boriani G, Brugada J, Deharo JC, Hindriks G, et al. Statistics on the use of cardiac electronic devices and electrophysiological procedures in 55 countries: 2013 ESC report from the European Heart Rhythm Association (EHRA). Europace. 2014;16 Suppl 1:11-78.

  12. Cano O, Pombo M, Fidalgo ML, Lorente D, Coma R. Registro Español de Marcapasos. XIV Informe Oficial de la Sección de Estimulación Cardíaca de la Sociedad Española de Cardiología (2016). Rev Esp Cardiol [revista en Internet]. 2017 [citado Jun 2];70(12):[aprox. 30p]. Disponible en: https://www.revespcardiol.org/es-registro-espanol-marcapasos-xiv-informe-articulo-S0300893217305134.

  13. Pombo M, Cano O, Lorente D, Chimeno J. Registro Español de Marcapasos. XV Informe Oficial de la Sección de Estimulación Cardíaca de la Sociedad Española de Cardiología (2017). Rev Esp Cardiol [revista en Internet]. 2018 [citado 2 Jun 2020];71(12):[aprox. 20p]. Disponible en: https://www.revespcardiol.org/es-pdf-S0300893218304731.

  14. Cano O, Pombo M, Lorente D, Chimeno J. Registro Español de Marcapasos. XVI Informe Oficial de la Sección de Estimulación Cardíaca de la Sociedad Española de Cardiología (2018). Rev Esp Cardiol [revista en Internet]. 2019 [citado 2 Jun 2020];72(11):[aprox. 22p]. Disponible en: https://www.revespcardiol.org/es-pdf-S0300893219303173.

  15. Romero AR, Fernández FI, Dominguez RJ, Santos A, Arias W. Peculiaridades clínica-epidemiológicas de pacientes sometidos a estimulación cardíaca eléctrica permanente. CCM [revista en Internet]. 2013 [citado 2 Jun 2020];17(4):[aprox. 12p]. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1560-43812013000400004&lng=es.

  16. Coll Y, Viera B. Comportamiento de la estimulación cardíaca en Cienfuegos durante el quinquenio 2005-2009. Medisur [revista en Internet]. 2011 [citado 2 Jun 2020];9(1):[aprox. 10p]. Disponible en: http://www.medisur.sld.cu/index.php/medisur/article/view/1300.

  17. Echazabal M, Cruz R, Hernández N, Díaz J. Características clínicas de pacientes que recibieron implante, reimplante o cambio de generador de marcapasos permanentes. Finlay [revista en Internet]. 2018 [citado 2 Jun 2020];8(4):[aprox. 16p]. Disponible en: http://revfinlay.sld.cu/index.php/finlay/article/view/615/1722.

  18. Vardas PE, Auricchio A, Blanc JJ, Daubert JC, Drexler H, Ector H, et al. Guidelines for cardiac pacing and cardiac resynchronization therapy: the task force for cardiac pacing and cardiac resynchronization therapy of the European Society of Cardiology. Developed in collaboration with the European Heart Rhythm Association. Eur Heart J. 2007;28(18):2256-95.

  19. Ochagavía CA, Baigorri GF. Selección del modo de estimulación del marcapasos. Hospital de Sabadell. España. Med Intensiva [revista en Internet]. 2006 [citado 3 Jun 2020];30(5):[aprox. 10p]. Disponible en: https://www.medintensiva.org/es-seleccion-del-modo-estimulacion-del-articulo-13091166.

  20. Udo EO, Zuithoff NP, Van Helmel NM, Carel CC, Thijs H, Pieter AD, et al. Incidence and predictor of short- and long- term complications in pacemaker therapy: the FOLLOWPACE STUDY. Heart Rhythm. 2012;9(5):728-35.

  21. Zhang S, Gaiser S, Kolominsky PL. Cardiac implant registries 2006-2016: a systematic review and summary of global experiences. BMJ Open. 2018;8(4):e019039.

  22. Brignole M, Auricchio A, Barón Esquivias G, Bordachar P, BorianiG, Breithardt O, et al. Guía de práctica clínica de la ESC 2013 sobre estimulación cardíaca y terapia de resincronización cardíaca. Rev Esp Cardiol [revista en Internet]. 2014 [citado 2 Jun 2020];67(1):[aprox. 10p]. Disponible en: https://www.revespcardiol.org/es-pdf-S0300893213005381.

  23. Toff WD, Camm AJ, Skehan JD. Single-chamber versus dual-chamber pacing for high-grade atrioventricular block. N Engl J Med [revista en Internet]. 2015 [citado 3 Jun 2020];353:[aprox. 20p]. Disponible en: https://www.nejm.org/doi/10.1056/NEJMoa042283?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub 0pubmed.

  24. Dharod A, Soliman E, Dawood F, Chen H, Shea S, Nazarian S, Bertoni A. Association of Asymptomatic Bradycardia with Incident Cardiovascular Disease and Mortality The Multi-Ethnic Study of Atherosclerosis (MESA). JAMA Intern Med [revista en Internet]. 2016 [citado 2 Jun 2020];176(2):[aprox. 9p]. Disponible en: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2482350.

  25. Santos M, Pupo P. Factores de riesgo de aparición de bloqueo auriculoventricular completo en el infarto de cara inferior. Rev Cubana Cardiol Cir Cardiovasc [revista en Internet]. 2016 [citado 8 Jun 2020];22(1):[aprox. 16p]. Disponible en: https://www.medigraphic.com/pdfs/cubcar/ccc-2016/ccc161d.pdf.




2020     |     www.medigraphic.com